Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Long-Term Deferred Tax (2022 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $201.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax fell 3.22% year-over-year to $201.3 million, compared with a TTM value of $201.3 million through Sep 2025, down 3.22%, and an annual FY2024 reading of $211.2 million, down 3.71% over the prior year.
  • Long-Term Deferred Tax was $201.3 million for Q3 2025 at Kiniksa Pharmaceuticals International, down from $205.5 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $219.3 million in Q4 2023 and bottomed at $184.4 million in Q1 2023.
  • Average Long-Term Deferred Tax over 4 years is $202.0 million, with a median of $204.3 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax rose 18.22% in 2023, then decreased 3.71% in 2024.
  • Year by year, Long-Term Deferred Tax stood at $185.5 million in 2022, then increased by 18.22% to $219.3 million in 2023, then dropped by 3.71% to $211.2 million in 2024, then decreased by 4.67% to $201.3 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for KNSA at $201.3 million in Q3 2025, $205.5 million in Q2 2025, and $208.2 million in Q1 2025.